Milk Fat Globule Membrane Attenuates Acute Colitis and Secondary Liver Injury by Improving the Mucus Barrier and Regulating the Gut Microbiota

Zhenhua Wu, Xiaoyi Liu, Shimeng Huang, Tiantian Li, Xiangyu Zhang, Jiaman Pang, Junying Zhao, Lijun Chen, Bing Zhang, Junjun Wang, Dandan HanFrontiers in Immunology 2022 · DOI

Abstract

Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations, notably hepatic injury. Milk fat globule membrane (MFGM), a bioactive component of milk, possesses significant anti-inflammatory potential. This study investigated the prophylactic effects of MFGM on dextran sulfate sodium (DSS)-induced acute colitis and secondary liver injury in mice. Prophylactic MFGM treatment significantly mitigated clinical symptoms, including body weight loss and disease activity index (DAI) scores, while preserving colonic length and histological integrity. Mechanistically, MFGM strengthened the intestinal mucus barrier by upregulating mucin and antimicrobial peptide genes, rebalanced the gut microbiota by enriching beneficial genera like Faecalibaculum, and reduced hepatic oxidative stress. These findings suggest MFGM as a promising dietary intervention for managing IBD and its systemic complications.

Introduction

Inflammatory Bowel Disease (IBD) is a chronic condition characterized by uncontrolled immune responses in the gastrointestinal tract. However, IBD is rarely limited to the gut; approximately 5% of patients develop secondary hepatobiliary disorders, such as fatty liver or cirrhosis, through the "gut-liver axis." When the intestinal barrier fails, toxins and bacteria translocate to the liver, causing secondary damage. While Milk Fat Globule Membrane (MFGM)—the bioactive trilayer surrounding fat droplets in milk—is known for its anti-inflammatory properties, its specific role in protecting the gut-liver axis remained poorly understood. This study sought to determine if MFGM could serve as a dietary intervention to prevent both primary intestinal inflammation and subsequent hepatic injury.

Methods

The researchers utilized a C57BL/6J mouse model of colitis. The experimental design involved a 21-day prophylactic phase where mice received MFGM via oral gavage, followed by a 7-day challenge with 4% Dextran Sulfate Sodium (DSS) in their drinking water to induce acute colitis. A multi-omics approach was employed to map protective mechanisms, including transcriptomics (RNA-seq) of colonic and hepatic tissues, 16S rRNA sequencing of fecal microbiota, and histological analysis using H&E and Alcian blue staining. Biochemical assays quantified cytokines (IL-1β, IL-6, IL-10) and oxidative stress markers (SOD, CAT, MDA).

Results

Clinical and Histological Improvements

Mice treated with MFGM showed significantly less body weight loss and lower Disease Activity Index (DAI) scores compared to the DSS-only group. Furthermore, MFGM treatment effectively prevented the colonic shortening typically observed in acute colitis.

MFGM treatment reduces Disease Activity Index (DAI) and prevents colonic shortening in DSS-induced colitis.

Histological examination via H&E staining confirmed that MFGM-treated mice maintained superior tissue integrity, suffering significantly less crypt loss and structural damage than untreated colitis mice.

H&E staining demonstrates that MFGM preserves colonic histological structure and reduces crypt loss compared to the DSS-only group.

Molecular and Microbiome Modulation

MFGM treatment suppressed pro-inflammatory cytokines (IL-1β and IL-6) while boosting the anti-inflammatory cytokine IL-10 in both the colon and liver. Transcriptomic analysis revealed a striking upregulation of barrier-associated genes, including MUC2, MUC4, Reg3b, and Reg3g. These genes encode mucins and antimicrobial peptides that form a "chemical wall" against pathogens. Microbiome analysis showed that MFGM enriched beneficial genera such as Faecalibaculum and Roseburia, which are known butyrate producers that support colonocyte health.

Secondary Liver Protection

The protection extended to the liver, where MFGM treatment significantly lowered hepatic enzymes (AST and ALT) and reduced levels of Malondialdehyde (MDA), a marker of lipid peroxidation. This was linked to the upregulation of the glutathione transferase activity pathway, boosting the liver's internal antioxidant defenses.

Discussion and Conclusion

The study demonstrates that MFGM acts as a potent prophylactic agent against acute colitis and associated secondary liver injury. By fortifying the intestinal mucus barrier and promoting a healthy gut microbiome, MFGM mitigates systemic inflammation and reduces hepatic oxidative stress. A strong correlation was found between colonic barrier integrity (specifically Reg3 levels) and reduced hepatic injury markers, reinforcing the critical role of the gut-liver axis. While this study focused on prophylactic treatment, future research should explore MFGM's therapeutic potential in existing colitis and other liver conditions. These findings highlight MFGM as a valuable functional food supplement for maintaining gut and liver health.

Summary updated

Abstract

Objective Inflammatory bowel disease (IBD) often occurs along with extraintestinal manifestations, including hepatic injury. Milk fat globule membrane (MFGM) is an active substance with a potential anti-inflammation activity. However, its alleviated effect and mechanisms in IBD as well as the IBD-induced secondary liver injury are still unclear. Methods C57BL/6J mice were administered with a 21-day oral gavage of MFGM, followed by 7 days of drinking water with 4% dextran sulfate sodium (DSS). Disease activity index (DAI), histological features, and cytokines of the colon and liver were evaluated. Then, RNA-seq of the colon and liver was conducted. The gut microbiota was assessed by analyzing 16S rRNA gene sequences, and finally the integrity and the function of the mucus barrier were evaluated by Alcian blue staining, real-time quantitative PCR, and ELISA. Results Prophylactic MFGM treatment was effective against colitis to include effects in body weight loss, DAI score, colonic length, intestinal pathology, and histological score. Additionally, prophylactic MFGM decreased the levels of interleukin (IL)-1β, IL-6, and myeloperoxidase in colonic tissue, while it increased the IL-10 level. Moreover, the gene expressions of MUC2 , MUC4 , Reg3b , and Reg3g associated with the production of the molecular mediator of immune response, membrane invagination, and response to protozoan were strikingly upregulated when administered with MFGM. On the other hand, the beneficial effects of MFGM were related to the enriched abundance of genera such as Faccalibacumum and Roseburia in feces samples. Consistently, the administration of MFGM was also found to alleviate DSS-induced hepatic injury. Furthermore, the glutathione transferase activity pathway was enriched in the liver of MFGM-treated mice after DSS administration. Mechanistically, prophylactic MFGM enhanced the mucosal barrier by increasing the gene levels of Reg3b and Reg3g . Meanwhile, the alleviation of MFGM on liver injury was dependent on the reduced hepatic oxidative stress. Conclusions MFGM attenuated colitis and hepatic injury by maintaining the mucosal barrier and bacterial community while inhibiting oxidative stress, which might be an effective therapy of hepatic injury secondary to IBD.
BibTeX
@inproceedings{wu2022milk,
  author = {Zhenhua Wu and Xiaoyi Liu and Shimeng Huang and Tiantian Li and Xiangyu Zhang and Jiaman Pang and Junying Zhao and Lijun Chen and Bing Zhang and Junjun Wang and Dandan Han},
  title = {{Milk Fat Globule Membrane Attenuates Acute Colitis and Secondary Liver Injury by Improving the Mucus Barrier and Regulating the Gut Microbiota}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.865273},
}
Figure